Hyperforin	0	10	B-Drug_or_compound
blocks	11	17	O
neutrophil	18	28	B-Cell
activation	29	39	O
of	40	42	O
matrix	43	49	B-Gene_or_gene_product
metalloproteinase	50	67	I-Gene_or_gene_product
-	67	68	I-Gene_or_gene_product
9	68	69	I-Gene_or_gene_product
,	69	70	O
motility	71	79	O
and	80	83	O
recruitment	84	95	O
,	95	96	O
and	97	100	O
restrains	101	110	O
inflammation	111	123	O
-	123	124	O
triggered	124	133	O
angiogenesis	134	146	O
and	147	150	O
lung	151	155	B-Organ
fibrosis	156	164	O
.	164	165	O

Hyperforin	167	177	B-Drug_or_compound
(	178	179	O
Hyp	179	182	B-Drug_or_compound
)	182	183	O
,	183	184	O
a	185	186	O
polyphenol	187	197	O
-	197	198	O
derivative	198	208	O
of	209	211	O
St	212	214	O
.	214	215	O

John	216	220	B-Organism
'	220	221	I-Organism
s	221	222	I-Organism
wort	223	227	I-Organism
(	228	229	O
Hypericum	229	238	B-Organism
perforatum	239	249	I-Organism
)	249	250	O
,	250	251	O
has	252	255	O
emerged	256	263	O
as	264	266	O
key	267	270	O
player	271	277	O
not	278	281	O
only	282	286	O
in	287	289	O
the	290	293	O
antidepressant	294	308	O
activity	309	317	O
of	318	320	O
the	321	324	O
plant	325	330	O
but	331	334	O
also	335	339	O
as	340	342	O
an	343	345	O
inhibitor	346	355	O
of	356	358	O
bacteria	359	367	O
lymphocyte	368	378	B-Cell
and	379	382	O
tumor	383	388	B-Cell
cell	389	393	I-Cell
proliferation	394	407	O
,	407	408	O
and	409	412	O
matrix	413	419	B-Gene_or_gene_product
proteinases	420	431	I-Gene_or_gene_product
.	431	432	O

We	433	435	O
tested	436	442	O
whether	443	450	O
as	451	453	O
well	454	458	O
as	459	461	O
inhibiting	462	472	O
leukocyte	473	482	B-Gene_or_gene_product
elastase	483	491	I-Gene_or_gene_product
(	492	493	O
LE	493	495	B-Gene_or_gene_product
)	495	496	O
activity	497	505	O
,	505	506	O
Hyp	507	510	B-Drug_or_compound
might	511	516	O
be	517	519	O
effective	520	529	O
in	530	532	O
containing	533	543	O
both	544	548	O
polymorphonuclear	549	566	B-Cell
neutrophil	567	577	I-Cell
(	578	579	I-Cell
PMN	579	582	I-Cell
)	582	583	I-Cell
leukocyte	584	593	I-Cell
recruitment	594	605	O
and	606	609	O
unfavorable	610	621	O
eventual	622	630	O
tissue	631	637	B-Tissue
responses	638	647	O
.	647	648	O

The	649	652	O
results	653	660	O
show	661	665	O
that	666	670	O
,	670	671	O
without	672	679	O
affecting	680	689	O
in	690	692	O
vitro	693	698	O
human	699	704	B-Organism
PMN	705	708	B-Cell
viability	709	718	O
and	719	722	O
chemokine	723	732	O
-	732	733	O
receptor	733	741	O
expression	742	752	O
,	752	753	O
Hyp	754	757	B-Drug_or_compound
(	758	759	O
as	759	761	O
stable	762	768	O
dicyclohexylammonium	769	789	B-Drug_or_compound
salt	790	794	I-Drug_or_compound
)	794	795	O
was	796	799	O
able	800	804	O
to	805	807	O
inhibit	808	815	O
in	816	818	O
a	819	820	O
dose	821	825	O
-	825	826	O
dependent	826	835	O
manner	836	842	O
their	843	848	O
chemotaxis	849	859	O
and	860	863	O
chemoinvasion	864	877	O
(	878	879	O
IC50	879	883	O
=	883	884	O
1	884	885	O
microM	886	892	O
for	893	896	O
both	897	901	O
)	901	902	O
;	902	903	O
this	904	908	O
effect	909	915	O
was	916	919	O
associated	920	930	O
with	931	935	O
a	936	937	O
reduced	938	945	O
expression	946	956	O
of	957	959	O
the	960	963	O
adhesion	964	972	O
molecule	973	981	O
CD11b	982	987	B-Gene_or_gene_product
by	988	990	O
formyl	991	997	B-Drug_or_compound
-	997	998	I-Drug_or_compound
Met	998	1001	I-Drug_or_compound
-	1001	1002	I-Drug_or_compound
Leu	1002	1005	I-Drug_or_compound
-	1005	1006	I-Drug_or_compound
Phe	1006	1009	I-Drug_or_compound
-	1009	1010	O
stimulated	1010	1020	O
neutrophils	1021	1032	B-Cell
and	1033	1036	O
block	1037	1042	O
of	1043	1045	O
LE	1046	1048	B-Gene_or_gene_product
-	1048	1049	O
triggered	1049	1058	O
activation	1059	1069	O
of	1070	1072	O
the	1073	1076	O
gelatinase	1077	1087	B-Gene_or_gene_product
matrix	1088	1094	I-Gene_or_gene_product
metalloproteinase	1095	1112	I-Gene_or_gene_product
-	1112	1113	I-Gene_or_gene_product
9	1113	1114	I-Gene_or_gene_product
.	1114	1115	O

PMN	1116	1119	B-Cell
-	1119	1120	O
triggered	1120	1129	O
angiogenesis	1130	1142	O
is	1143	1145	O
also	1146	1150	O
blocked	1151	1158	O
by	1159	1161	O
both	1162	1166	O
local	1167	1172	O
injection	1173	1182	O
and	1183	1186	O
daily	1187	1192	O
i	1193	1194	O
.	1194	1195	O
p	1195	1196	O
.	1196	1197	O
administration	1198	1212	O
of	1213	1215	O
the	1216	1219	O
Hyp	1220	1223	B-Drug_or_compound
salt	1224	1228	O
in	1229	1231	O
an	1232	1234	O
interleukin	1235	1246	B-Gene_or_gene_product
-	1246	1247	I-Gene_or_gene_product
8	1247	1248	I-Gene_or_gene_product
-	1248	1249	O
induced	1249	1256	O
murine	1257	1263	B-Organism
model	1264	1269	O
.	1269	1270	O

Furthermore	1271	1282	O
,	1282	1283	O
i	1284	1285	O
.	1285	1286	O
p	1286	1287	O
.	1287	1288	O
treatment	1289	1298	O
with	1299	1303	O
Hyp	1304	1307	B-Drug_or_compound
reduces	1308	1315	O
acute	1316	1321	O
PMN	1322	1325	B-Cell
recruitment	1326	1337	O
and	1338	1341	O
enhances	1342	1350	O
resolution	1351	1361	O
in	1362	1364	O
a	1365	1366	O
pulmonary	1367	1376	O
bleomycin	1377	1386	B-Drug_or_compound
-	1386	1387	O
induced	1387	1394	O
inflammation	1395	1407	O
model	1408	1413	O
,	1413	1414	O
significantly	1415	1428	O
reducing	1429	1437	O
consequent	1438	1448	O
fibrosis	1449	1457	O
.	1457	1458	O

These	1459	1464	O
results	1465	1472	O
indicate	1473	1481	O
that	1482	1486	O
Hyp	1487	1490	B-Drug_or_compound
is	1491	1493	O
a	1494	1495	O
powerful	1496	1504	O
anti	1505	1509	O
-	1509	1510	O
inflammatory	1510	1522	O
compound	1523	1531	O
with	1532	1536	O
therapeutic	1537	1548	O
potential	1549	1558	O
,	1558	1559	O
and	1560	1563	O
they	1564	1568	O
elucidate	1569	1578	O
mechanistic	1579	1590	O
keys	1591	1595	O
.	1595	1596	O

